Valuation: BriaCell Therapeutics Corp.

Market Cap 29.89M 26.57M 24.63M 22.41M 42.28M 2.84B 42.96M 296M 116M 1.48B 112M 110M 4.72B P/E 2024
-2.56x
P/E 2025 -0.12x
Enterprise Value 12.02M 10.69M 9.91M 9.01M 17.01M 1.14B 17.28M 119M 46.69M 596M 45.13M 44.17M 1.9B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.96%
Yield 2024 *
-
Yield 2025 -
09-14 BriaCell Therapeutics Corp Receives Seventh Consecutive Positive DSMB Recommendation For Pivotal Phase 3 Bria-ABC Study Of Bria-IMT Plus Immune Checkpoint Inhibitor CI
09-11 Neonc Technologies Holdings, Briacell Therapeutics and Oncolytics Biotech Have Report Clinical and Regulatory Developments Across Brain, Breast and Colorectal Cancer CI
09-08 BriaCell Therapeutics Corp. Expands Pivotal Phase 3 Metastatic Breast Cancer Study To Memorial Sloan Kettering Cancer Center CI
09-02 Certain Common Shares of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-02 Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-02 Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-02 Certain Restricted Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
09-02 Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 2-SEP-2026. CI
08-24 BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+ CI
08-05 BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study MT
08-05 Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer CI
07-16 BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study MT
07-16 BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer CI
1 day-8.96%
1 week-13.01%
Current month-20.00%
1 month-2.01%
3 months-8.61%
6 months-17.43%
Current year-50.20%
1 week 4.8
Extreme 4.8
5.56
1 month 4.8
Extreme 4.8
6.23
Current year 3.68
Extreme 3.68
16.5
1 year 3.68
Extreme 3.68
20.4
3 years 3.68
Extreme 3.68
1,200
5 years 3.68
Extreme 3.68
2,362.5
10 years 3.68
Extreme 3.68
11,250.11
Manager TitleAgeSince
Chief Executive Officer 70 31/10/2016
Director of Finance/CFO 54 31/01/2016
Chief Tech/Sci/R&D Officer 65 15/02/2022
Director TitleAgeSince
Director/Board Member 70 31/10/2016
Chairman 41 23/04/2019
Director/Board Member 74 06/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
07/07/26 Tax

Director

45,000 0.5173%
07/07/26 Tax

Director

15,000 0.1724%
07/07/26 Option

Chief Financial Officer

28,257 0.3248%
Change 5-day change 1-year change 3-year change Capi.($)
-8.96%-13.01%-71.61%-99.58% 32.85M
-6.60%-8.56%+42.79%+64.16% 68.98B
-4.09%-0.11%+2.31%+54.81% 53.15B
+0.03%+5.56%+10.18%+41.75% 50.83B
-1.53%+2.70%+29.72%+34.13% 44.61B
-1.34%+4.12%+16.05%+112.18% 42.53B
-5.97%-6.22%+258.21%+421.57% 40.57B
+6.53%+8.02%+15.74%+53.94% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
-2.76%-9.54%-16.53%-9.55% 22.66B
Average -2.56%-0.71%+31.83%+67.18% 37.98B
Weighted average by Cap. -2.43%-0.10%+44.73%+90.23%

Financials

2024 2025
Net sales - -
Net income -4.79M -4.26M -3.95M -3.59M -6.78M -455M -6.89M -47.45M -18.6M -237M -17.98M -17.6M -756M -26.31M -23.39M -21.68M -19.72M -37.22M -2.5B -37.82M -261M -102M -1.3B -98.75M -96.65M -4.15B
Net Debt -862K -766K -710K -646K -1.22M -81.82M -1.24M -8.54M -3.35M -42.7M -3.24M -3.17M -136M -17.87M -15.88M -14.72M -13.39M -25.27M -1.7B -25.68M -177M -69.37M -885M -67.05M -65.62M -2.82B
Projected Income Statement - Annual - BriaCell Therapeutics Corp.
Logo BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Employees
16
Date Price Change Volume
16/10/26 CA$4.880 -8.96% 15,457
15/10/26 CA$5.360 +2.10% 891
14/10/26 CA$5.250 -1.13% 2,967
13/10/26 CA$5.310 -5.35% 4,304
09/10/26 CA$5.610 +0.90% 1,100

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BriaCell Therapeutics Corp.